TL;DR

  • Connected medical devices are cyber-physical safety systems — A compromised insulin pump, pacemaker, or infusion pump can directly harm patients. Cybersecurity is patient safety, not just data protection.
  • TGA requires cybersecurity evidence for market approval — The Therapeutic Goods Administration (TGA) assesses cybersecurity as part of the medical device approval process for software-based and connected devices. Weak security can delay or block market entry.
  • Healthcare is Australia's #1 breach target — The health sector leads all industries in reported data breaches (OAIC, 2025). Medical device and biotech companies holding health data are in the crosshairs.
  • The average data breach costs AUD $4.26 million — IBM Cost of a Data Breach Report 2024, but healthcare breaches cost significantly more (AUD $10.93 million globally) due to regulatory impact and patient safety concerns.

Why Medical Devices & Biotech Businesses Are Cybersecurity Targets

Australia's medical technology and biotechnology sector contributes over AUD $4 billion annually to the economy and employs approximately 25,000 people across medical device manufacturing, diagnostics, biopharmaceuticals, and digital health technologies. The sector sits at the intersection of healthcare innovation, sensitive health data, and patient safety — making it uniquely attractive to cybercriminals. The Australian Signals Directorate's Annual Cyber Threat Report 2024–2025 identifies the health sector as the most targeted industry, and medical device manufacturers are part of this threat landscape.​‌‌​​​‌‌‍​‌‌‌‌​​‌‍​‌‌​​​‌​‍​‌‌​​‌​‌‍​‌‌‌​​‌​‍​‌‌‌​​‌‌‍​‌‌​​‌​‌‍​‌‌​​​‌‌‍​‌‌‌

​‌​‌‍​‌‌‌​​‌​‍​‌‌​‌​​‌‍​‌‌‌​‌​​‍​‌‌‌‌​​‌‍​​‌​‌‌​‌‍​‌‌​​‌‌‌‍​‌‌‌​‌​‌‍​‌‌​‌​​‌‍​‌‌​​‌​​‍​‌‌​​‌​‌‍​​‌​‌‌​‌‍​‌‌​‌‌​‌‍​‌‌​​‌​‌‍​‌‌​​‌​​‍​‌‌​‌​​‌‍​‌‌​​​‌‌‍​‌‌​​​​‌‍​‌‌​‌‌​​‍​​‌​‌‌​‌‍​‌‌​​‌​​‍​‌‌​​‌​‌‍​‌‌‌​‌‌​‍​‌‌​‌​​‌‍​‌‌​​​‌‌‍​‌‌​​‌​‌‍​‌‌‌​​‌‌‍​​‌​‌‌​‌‍​‌‌​​​‌​‍​‌‌​‌​​‌‍​‌‌​‌‌‌‌‍​‌‌‌​‌​​‍​‌‌​​‌​‌‍​‌‌​​​‌‌‍​‌‌​‌​​​

Medical devices have evolved from standalone equipment to connected, software-defined products that integrate with hospital networks, electronic health records (EHR), and cloud platforms. An insulin pump or cardiac monitor that transmits data to a clinician's dashboard creates an attack pathway that could be exploited to harm patients directly. In 2019, the U.S. FDA confirmed that vulnerabilities in certain cardiac implantable electronic devices could allow unauthorized modification of device settings — demonstrating that medical device cybersecurity is a life-safety issue, not just a data protection issue. While Australian hospitals have not experienced a widely publicised patient-harming medical device breach to date, the risk is real and regulators are taking notice.

Biotechnology and medical device companies also hold valuable intellectual property: proprietary algorithms, diagnostic methodologies, genomic data, and clinical trial results. State-sponsored actors and competitors may target these companies to exfiltrate research data or compromise clinical trial integrity. For early-stage biotech firms, a breach that exposes pre-patent research or compromises clinical trial data can destroy company value overnight. The dual exposure — patient safety risk from device vulnerabilities and commercial risk from IP theft — makes cybersecurity a strategic priority for the sector.​‌‌​​​‌‌‍​‌‌‌‌​​‌‍​‌‌​​​‌​‍​‌‌​​‌​‌‍​‌‌‌​​‌​‍​‌‌‌​​‌‌‍​‌‌​​‌​‌‍​‌‌​​​‌‌‍​‌‌‌​‌​‌‍​‌‌‌​​‌​‍​‌‌​‌​​‌‍​‌‌‌​‌​​‍​‌‌‌‌​​‌‍​​‌​‌‌​‌‍​‌‌​​‌‌‌‍​‌‌‌​‌​‌‍​‌‌​‌​​‌‍​‌‌​​‌​​‍​‌‌​​‌​‌‍​​‌​‌‌​‌‍​‌‌​‌‌​‌‍​‌‌​​‌​‌‍​‌‌​​‌​​‍​‌‌​‌​​‌‍​‌‌​​​‌‌‍​‌‌​​​​‌‍​‌‌​‌‌​​‍​​‌​‌‌​‌‍​‌‌​​‌​​‍​‌‌​​‌​‌‍​‌‌‌​‌‌​‍​‌‌​‌​​‌‍​‌‌​​​‌‌‍​‌‌​​‌​‌‍​‌‌‌​​‌‌‍​​‌​‌‌​‌‍​‌‌​​​‌​‍​‌‌​‌​​‌‍​‌‌​‌‌‌‌‍​‌‌‌​‌​​‍​‌‌​​‌​‌‍​‌‌​​​‌‌‍​‌‌​‌​​​

The Top 3 Cybersecurity Threats for Medical Devices & Biotech

1. Connected Medical Device Exploitation

Connected medical devices — insulin pumps, pacemakers, infusion pumps, patient monitors, robotic surgery systems, and diagnostic equipment — present unique cybersecurity challenges. These devices often run on embedded operating systems that may be end-of-life and unpatchable, have limited processing power that precludes modern security controls, and were designed under regulatory frameworks that prioritised safety over security. When these devices are connected to hospital networks or the internet for remote monitoring, they become exposed to attack vectors that were not anticipated during design.

The threat is not theoretical. Research has demonstrated vulnerabilities in insulin pumps that could allow attackers to deliver incorrect insulin doses, vulnerabilities in cardiac devices that could allow unauthorized pacing changes, and vulnerabilities in hospital imaging systems that could allow ransomware deployment. In 2017, the WannaCry ransomware attack affected National Health Service (NHS) hospitals in the UK, forcing cancellation of surgeries and medical appointments — medical devices were not directly targeted, but hospital systems' inability to access device data caused patient care disruption. For medical device manufacturers, a demonstrated vulnerability can trigger TGA recalls, FDA safety communications (for exported products), and liability exposure.

2. Ransomware Targeting Research and Clinical Data

Biotechnology companies and medical device manufacturers hold data that is both sensitive and irreplaceable: clinical trial results, patient study data, genomic databases, and pre-submission research. Ransomware attacks that encrypt this data can delay product development, miss clinical trial milestones, and compromise regulatory submissions. The ASD's 2024–2025 Annual Cyber Threat Report identifies healthcare — including medical research and biotechnology — as a top target for ransomware actors.

For medical device companies, ransomware that affects manufacturing systems can halt production of life-critical devices. For biotech firms, ransomware that compromises quality control data or batch records can trigger regulatory holds on product release. The Cyber Security Act 2024 introduces mandatory ransomware payment reporting from 30 May 2025 for entities with turnover above AUD $3 million — meaning that a medical device or biotech company's decision to pay or not pay ransom must be reported to the ASD within 72 hours. The publication of clinical trial data or patient health information would additionally trigger OAIC notification obligations and potential TGA reporting requirements.

3. Intellectual Property Theft and Research Data Exfiltration

Biotechnology and medical device companies invest heavily in R&D, and the resulting intellectual property is highly valuable to competitors and state-sponsored actors seeking to accelerate their own development. Exfiltration of pre-patent research, proprietary algorithms, diagnostic methodologies, or clinical trial data can cause long-term commercial harm and, for public companies, can significantly affect share price. Insider threats — both malicious insiders and negligent employees — pose a significant risk. A departing researcher taking proprietary data to a competitor, or a contractor inadvertently exposing sensitive research through unauthorised cloud storage, can erode competitive advantage.

Genomic and health data present particular ethical and regulatory challenges. Australian Genomics and the Medical Research Future Fund have invested heavily in genomic research, and the resulting datasets are both scientifically valuable and personally identifiable. Exfiltration of genomic data that can be linked to identifiable individuals would breach the Privacy Act and likely trigger NDB notification obligations. The Office of the Australian Information Commissioner has taken enforcement action against health sector organisations for inadequate protection of health data, and medical research institutions are not exempt from these obligations.

Compliance Requirements for Medical Devices & Biotech

Australian medical device and biotechnology companies face a complex regulatory environment that spans cybersecurity, privacy, and therapeutic goods regulation:

Therapeutic Goods Administration (TGA) Regulations The TGA regulates medical devices in Australia under the Therapeutic Goods Act 1989. Software-based medical devices and connected medical devices are subject to TGA scrutiny regarding cybersecurity. The TGA's "Software as a Medical Device" guidelines and the Australian Regulatory Guidelines for Medical Devices (ARGMD) require manufacturers to consider cybersecurity risks as part of the overall safety and risk management process. For devices seeking inclusion in the Australian Register of Therapeutic Goods (ARTG), manufacturers must provide evidence of cybersecurity risk assessment and mitigation. The TGA also requires post-market monitoring of cybersecurity vulnerabilities — demonstrated vulnerabilities must be reported, and remediation plans may be required.

Privacy Act 1988 (Cth) and Australian Privacy Principles (APPs) Medical device and biotech companies that hold personal health information are bound by the Privacy Act and APPs. Health information is recognised as "sensitive information" under the Privacy Act, attracting higher obligations. APP 11 requires "reasonable steps" to protect health information, and the Notifiable Data Breach (NDB) scheme requires notification to the OAIC and affected individuals of eligible data breaches. The Privacy and Other Legislation Amendment Act 2024 (effective 11 December 2024) strengthened enforcement: civil penalties can now reach AUD $50 million for serious or repeated breaches. Note: the small business exemption ($3M turnover threshold) does not apply to health service providers, which catches many medical device and biotech companies that process health data.

Cyber Security Act 2024 (Cth) Enacted in November 2024, the Cyber Security Act introduces mandatory ransomware payment reporting (effective 30 May 2025) for entities with annual turnover above AUD $3 million. Medical device and biotech companies in this bracket must report to the ASD within 72 hours of making or having made a ransom payment. The Act also enables the National Cyber Security Coordinator to request information and issue directions following significant cyber incidents.

Security of Critical Infrastructure Act 2018 (SOCI Act) Medical device manufacturers that supply to the health sector may be subject to SOCI Act obligations if they are considered part of the health critical infrastructure supply chain. The Act establishes a positive security obligation to maintain risk management programmes addressing cybersecurity hazards. Companies should confirm whether their activities trigger SOCI Act capture.

Clinical Trial Ethics and Research Governance For biotechnology companies conducting clinical trials, ethics committee approval and human research ethics requirements impose obligations to protect trial data and participant information. A cybersecurity breach that compromises clinical trial data may trigger reporting to ethics committees, the TGA, and potentially the NHMRC (National Health and Medical Research Council). Research governance frameworks increasingly expect cybersecurity risk assessment as part of trial design.

ASD Essential Eight While not legally mandated, the ASD's Essential Eight mitigation strategies are strongly endorsed for healthcare organisations and are increasingly expected by hospital networks and research institutions when procuring medical devices or partnering with biotech companies.

The lilMONSTER Security Checklist for Medical Devices & Biotech

These controls address the unique risk profile of medical device and biotech companies, where patient safety, IP protection, and regulatory compliance intersect:

  1. Secure-by-design development for medical devices — Build cybersecurity into the product development lifecycle from the outset. Conduct threat modelling and risk assessment during design. Follow secure coding practices, perform static and dynamic code analysis, and conduct penetration testing before regulatory submission. For connected devices, implement encryption, authentication, and secure boot mechanisms. Document your cybersecurity controls for TGA submissions — TGA reviewers will assess these as part of the overall safety evaluation.

  2. Inventory and risk classification of all medical devices — Maintain a comprehensive register of all medical devices you manufacture, sell, or deploy, including software version, known vulnerabilities, and cybersecurity controls. Classify devices by risk level: patient-safety-critical devices (e.g., insulin pumps, pacemakers) require the highest security controls, while non-connected diagnostic devices may have lower exposure. Prioritise remediation for high-risk devices that are network-connected or have internet exposure.

  3. Network segmentation and isolation for medical devices — Separate medical device networks from corporate IT networks. Use dedicated VLANs, firewalls, or network segmentation controls to limit communication between devices and other systems. Implement strict ingress/egress filtering: medical devices should only communicate with authorised endpoints using defined protocols. For hospital-deployed devices, work with hospital IT to ensure network segmentation aligns with hospital security policies.

  4. Patch and vulnerability management for devices and software — Establish processes for security updates throughout the device lifecycle. For devices that receive regular software updates, implement secure update mechanisms with code signing and integrity verification. For legacy devices that cannot be patched, implement compensating controls: network segmentation, application allow-listing, and strict access controls. Monitor vulnerability databases (e.g., NVD, ICS-CERT) for vulnerabilities affecting components you use.

  5. Encryption of data at rest and in transit — Encrypt all sensitive health data, clinical trial data, and research data, both in storage (databases, research systems, backup media) and in transit (device-to-cloud communications, API calls, data transfers). Use strong encryption standards (AES-256 for data at rest, TLS 1.3 for data in transit). Maintain an inventory of encrypted assets and encryption key management procedures. For medical devices transmitting patient data, encryption is increasingly expected by TGA and hospital procurement.

  6. Access controls for research and clinical data — Implement role-based access control so that staff only have access to the data and systems relevant to their role. Research assistants should not need access to patient-identifiable data where de-identified data would suffice. Use privileged access management for administrative accounts. Audit access logs monthly for suspicious activity — particularly access to high-value IP or pre-publication research. Multi-factor authentication should be mandatory for all systems containing sensitive data.

  7. Third-party and supply chain risk management — Assess the cybersecurity posture of significant suppliers and research partners: cloud platforms, contract research organisations (CROs), component suppliers, and software vendors. Include security clauses in contracts specifying minimum security standards, notification obligations, and liability for breaches. For software components, maintain a Software Bill of Materials (SBOM) to track known vulnerabilities.

  8. Incident response plan with patient safety protocols — Document exactly what happens in the first 72 hours of a breach: who isolates affected systems, who assesses patient safety impact, who notifies the TGA and OAIC, who manages communication with hospitals and patients, and who coordinates recall decisions if a device vulnerability is discovered. For devices already deployed in clinical settings, establish protocols for working with hospitals to address vulnerabilities without putting patients at risk. Test the plan annually with a tabletop exercise involving clinical, regulatory, and legal stakeholders.

How Much Does Cybersecurity Cost for a Medical Device & Biotech Business?

Cybersecurity is a cost of product development and regulatory compliance.

Spend What it covers
AUD $20,000–80,000/year SME essentials: Secure development training, penetration testing of devices and software, vulnerability scanning, TGA cybersecurity documentation support
AUD $80,000–300,000/year Mid-tier: Dedicated security personnel, managed security monitoring, secure SDLC integration, annual red teaming, third-party risk management
AUD $300,000–1,500,000/year Enterprise: CISO, in-house security team, advanced threat protection, clinical trial data protection, SOCI Act compliance programme

Cost of a breach for a medical device or biotech company:

  • Average healthcare data breach: AUD $10.93 million globally (IBM, 2024) — significantly higher than the cross-industry average
  • TGA product recall or safety advisory: costs vary widely but can involve product replacement costs, halted sales, and regulatory remediation
  • Delayed regulatory approval: opportunity cost from delayed market entry can amount to millions in lost revenue
  • IP theft: potentially company-ending for early-stage biotech firms where pre-patent research is the primary asset
  • OAIC civil penalty exposure: up to AUD $50 million for serious or repeated Privacy Act breaches
  • Clinical trial compromise: may require repeating trials, costing millions and delaying product approval by years

Cyber liability insurance for medical device and biotech companies typically costs AUD $10,000–100,000/year depending on revenue, product portfolio, and security posture. However, insurers are increasingly cautious about medical device liability, and policy exclusions for known device vulnerabilities or unpatched software are common. Cyber insurance may not cover product liability claims arising from cybersecurity-enabled device failures.

FAQ

A foundational cybersecurity programme for a small Australian medical device manufacturer typically starts at AUD $30,000–100,000 per year, covering secure development practices, penetration testing of devices and software, vulnerability management, TGA cybersecurity documentation support, and staff training. For connected devices, additional costs for secure boot, encryption, and authentication implementation are part of the product development budget. An annual device penetration test typically costs AUD $20,000–80,000 depending on device complexity. For context, the average healthcare data breach costs AUD $10.93 million globally, and a TGA recall can halt sales and require product replacement.

The greatest cybersecurity risk for connected medical devices is the potential for direct patient harm if an attacker exploits device vulnerabilities. Research has demonstrated that insulin pumps, pacemakers, and infusion pumps can be compromised to deliver incorrect treatments or modify device settings. This is not a data breach — it is a patient safety incident. For manufacturers, this risk creates liability exposure and regulatory action. The TGA expects cybersecurity to be integrated into device safety risk management, and demonstrated vulnerabilities can trigger recalls or safety advisories. Ransomware targeting research and clinical data is the second major threat, particularly for biotech firms.

ISO 27001 is not legally mandated by the TGA, but it provides a structured framework that demonstrates mature information security governance — which can support TGA submissions and reassure hospital procurement teams. Some medical device manufacturers adopt IEC 62304 (software lifecycle processes) and IEC 81001-5-1 (security for connected health devices) as sector-specific standards that align with regulatory expectations. lilMONSTER can assess whether ISO 27001, IEC 62304/81001-5-1, or a combination best fits your regulatory obligations and market requirements.

The TGA expects medical device manufacturers to conduct security testing as part of the overall risk management process. For connected devices and software-based medical devices, annual penetration testing is recommended as a baseline, and additional testing should be conducted after any significant software update or architectural change. Testing should cover both the device itself and any associated cloud services, mobile applications, or data transmission protocols. For devices seeking FDA approval (for export to the U.S.), FDA expectations align with annual testing or more frequent testing for high-risk devices. Test results should be documented for regulatory submissions.

If a medical device or biotech company suffers a significant cyber incident, multiple obligations may be triggered: (1) Notify the TGA if a device vulnerability is discovered that could affect patient safety — TGA may issue a safety advisory or require a recall. (2) Notify the OAIC under the Notifiable Data Breach scheme if health information or personal information was accessed. (3) Report ransom payments to the ASD within 72 hours (for companies with turnover >$3M, from 30 May 2025) under the Cyber Security Act 2024. (4) Notify hospitals and healthcare providers if deployed devices are affected — patient safety considerations may require device recalls or field corrections. (5) Engage with ethics committees if clinical trial data was compromised. (6) Consider ASX disclosure if the incident is material for a listed entity.

References

[1] Australian Signals Directorate (ASD), "Annual Cyber Threat Report 2024–2025," Australian Government, 2025. [Online]. Available: https://www.cyber.gov.au/about-us/view-all-content/reports-and-statistics/annual-cyber-threat-report-2024-2025

[2] IBM Security, "Cost of a Data Breach Report 2024," IBM Corporation, Jul. 2024. [Online]. Available: https://www.ibm.com/reports/data-breach

[3] Therapeutic Goods Administration (TGA), "Guidelines for Software as a Medical Device," Australian Government, 2024. [Online]. Available: https://www.tga.gov.au/

[4] Therapeutic Goods Administration (TGA), "Australian Regulatory Guidelines for Medical Devices (ARGMD)," Australian Government, 2024. [Online]. Available: https://www.tga.gov.au/

[5] Office of the Australian Information Commissioner (OAIC), "Notifiable Data Breaches Scheme," OAIC, 2024. [Online]. Available: https://www.oaic.gov.au/

[6] Australian Government, "Cyber Security Act 2024 (Cth)," Federal Register of Legislation, Nov. 2024. [Online]. Available: https://www.legislation.gov.au/

[7] Australian Government, "Security of Critical Infrastructure Act 2018 (Cth)," Federal Register of Legislation, 2024. [Online]. Available: https://www.legislation.gov.au/

[8] Australian Cyber Security Centre (ACSC), "Essential Eight Mitigation Strategies," Australian Government, 2024. [Online]. Available: https://www.cyber.gov.au/publications/essential-eight-mitigation-strategies

[9] TGA, "Medical Device Cybersecurity," TGA Safety Advisory, 2024. [Online]. Available: https://www.tga.gov.au/

[10] Medical Device Innovation Consortium (MDIC), "Medical Device Cybersecurity Certification," MDIC, 2024. [Online]. Available: https://mdic.org/

Need help securing your Medical Devices & Biotech business? Book a free consultation with lilMONSTER — Australia's no-BS cybersecurity team for SMBs.

Ready to strengthen your security?

Talk to lilMONSTER. We assess your risks, build the tools, and stay with you after the engagement ends. No clipboard-and-leave consulting.

Get a Free Consultation